Grant: Engage Grants Program
University of Toronto
$25,000.00
Determining optimal ultrasound exposure conditions for ultrasound-microbubble-based gene delivery to lung epithelium and endothelium
FY 2016-17
Summary
Acute respiratory distress syndrome (ARDS) is one of the commonest disorders in intensive care units and hasa mortality rate approaching 40%. It occurs when the smallest blood vessels in the lung become leaky, leadingto flooding of the lung and resulting in patients drowning on their own fluids. ARDS is one of the mostdifficult conditions to treat because of its patchy and uneven distribution, with some areas of relatively normallung being interspersed with other regions that are almost completely filled with liquid. This patchworkdistribution has the unintended consequence that treatments such as mechanical ventilation or inhaled drugspreferentially go to the normal regions of the lung instead of the injured, fluid-filled areas. Along the samelines, drugs that are given orally or by injection affect all the organs and tissues in the body, not just thedamaged regions of lung. This of course predisposes to undesirable side effects. In essence, the inability totarget just the injured regions of the lung in ARDS is one of the thorniest problems in critical care.In other parts of the body, ultrasound waves have been used to deliver restorative genes and medicines todiseased tissues. However, the medical and scientific community has long thought that ultrasoundadministration to the lung is impossible because air blocks ultrasound waves. Our team realized that becausethe injured lung is filled with fluid and not air, ultrasound waves can penetrate the injured regions of the lungwhile leaving the normal lung untouched. Taken a step further, ultrasound waves can be used to deliver genesand drugs just to the injured lung, sparing other organs in the body and sparing the normal (air-filled) regionsof the lung. In this proposal, MD Precision is asking Dr. Lee to determine the optimal ultrasound parameters todeliver genes and drugs to cultured epithelial and endothelial cells of the lung. This information will then beused by MD Precision to develop ultrasound technology to specifically target the injured lung in ARDS. Thisproposal is bringing together engineering and natural sciences experts to develop new technology to benefitCanadians.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
503493-2016
Name nom
Lee, Warren
Department département
Medicine, Department of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Determining optimal ultrasound exposure conditions for ultrasound-microbubble-based gene delivery to lung epithelium and endothelium
Keyword
NSERC
Application summary
Acute respiratory distress syndrome (ARDS) is one of the commonest disorders in intensive care units and hasa mortality rate approaching 40%. It occurs when the smallest blood vessels in the lung become leaky, leadingto flooding of the lung and resulting in patients drowning on their own fluids. ARDS is one of the mostdifficult conditions to treat because of its patchy and uneven distribution, with some areas of relatively normallung being interspersed with other regions that are almost completely filled with liquid. This patchworkdistribution has the unintended consequence that treatments such as mechanical ventilation or inhaled drugspreferentially go to the normal regions of the lung instead of the injured, fluid-filled areas. Along the samelines, drugs that are given orally or by injection affect all the organs and tissues in the body, not just thedamaged regions of lung. This of course predisposes to undesirable side effects. In essence, the inability totarget just the injured regions of the lung in ARDS is one of the thorniest problems in critical care.In other parts of the body, ultrasound waves have been used to deliver restorative genes and medicines todiseased tissues. However, the medical and scientific community has long thought that ultrasoundadministration to the lung is impossible because air blocks ultrasound waves. Our team realized that becausethe injured lung is filled with fluid and not air, ultrasound waves can penetrate the injured regions of the lungwhile leaving the normal lung untouched. Taken a step further, ultrasound waves can be used to deliver genesand drugs just to the injured lung, sparing other organs in the body and sparing the normal (air-filled) regionsof the lung. In this proposal, MD Precision is asking Dr. Lee to determine the optimal ultrasound parameters todeliver genes and drugs to cultured epithelial and endothelial cells of the lung. This information will then beused by MD Precision to develop ultrasound technology to specifically target the injured lung in ARDS. Thisproposal is bringing together engineering and natural sciences experts to develop new technology to benefitCanadians.